This “Perspective” article and the accompanying piece Risk, Prognosis, and Unintended Consequences in Kidney Allocation look at a recent proposal to change the allocation of deceased donor kidneys in the United States. The new system would use models which estimates a patient’s risk of death and a kidney’s risk of graft failure, and then allocates kidneys with the longest expected survival to those patients on the waiting list with longest expected survival. These two pieces explain the rationale and development of this proposal, as well as some potential negative outcomes of such a change.

Related Articles:

• Kidneys from Donors after Cardiac Death Provide Survival Benefit
• Perioperative Mortality and Long-term Survival Following Live Kidney Donation
• Anti-Human Leukocyte Antigen and Donor-Specific Antibodies Detected by Luminex Posttransplant Serve as Biomarkers for Chronic Rejection of Renal Allografts

This editorial provides critical analysis of the paper “In-Center Hemodialysis Six Times per Week versus Three Times per Week”.

Free full text provided by the New England Journal of Medicine.

Related Articles:

• Intensive Diabetes Therapy and Glomerular Filtration Rate in Type 1 Diabetes
• Therapeutic Interventions for Systemic Vasculitis
• In-Center Hemodialysis Six Times per Week versus Three Times per Week

Related Articles:

• Maintenance Immunosuppression in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
• Mycophenolate Mofetil vs Azathioprine for Remission Maintenance in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Trial
• Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis

This editorial provides insight into the interpretation of the article ‘A Randomized, Controlled Trial of Early versus Late Initiation of Dialysis‘.

Related Articles:

• A Randomized, Controlled Trial of Early versus Late Initiation of Dialysis
• Association between estimated glomerular filtration rate at initiation of dialysis and mortality
• Treatment of Anemia in Chronic Kidney Disease — Strategies Based on Evidence

This NEJM “Perspectives” article from the Food and Drug Administration discusses the data driving a need to re-evaluate the use of ESAs in the treatment of anemia due to chronic kidney disease.

Related Articles:

• The FDA’s Perspective on the Risk for Rapid Rise in Hemoglobin in Treating CKD Anemia: Quo Vadis
• Stage IV Chronic Kidney Disease
• Does TREAT Give the Boot to ESAs in the Treatment of CKD Anemia?

This editorial by Dr. Ajay Singh discusses the implications of TREAT in the context of the existing evidence base on the management of anemia due to chronic kidney disease.

Related Articles:

• The FDA’s Perspective on the Risk for Rapid Rise in Hemoglobin in Treating CKD Anemia: Quo Vadis
• Treatment of Anemia in Chronic Kidney Disease — Strategies Based on Evidence
• Erythropoiesis-Stimulating Agents — Time for a Reevaluation